John F. Paolini sold $1.8M of KNSA
CHIEF MEDICAL OFFICER at Kiniksa Pharmaceuticals International, plc. 40,000 shares at an average of $44.82, traded Mar 2, 2026, filed Mar 4, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.8M at market
- +10Share of holdings soldSold 39% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001741533-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | MOption exercise Class A Ordinary Share10b5-1 | +40,000 | $10.36 | $414k | 101,324 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Class A Ordinary Share10b5-1 | -12,063 | $44.20 | $533k | 89,261 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Class A Ordinary Share10b5-1 | -22,223 | $44.88 | $997k | 67,038 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Class A Ordinary Share10b5-1 | -5,714 | $45.92 | $262k | 61,324 | Mar 4, 2026 |
| Mar 2, 2026 | MOption exercise Share Optionderivative10b5-1 | -40,000 | $0.00 | $0 | 58,424 | Mar 4, 2026 |
Related signals
Other insiders at Kiniksa Pharmaceuticals International, plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Kiniksa Pharmaceuticals International, plc | Michael R Megna CHIEF ACCOUNTING OFFICER | $369k 4,600 shares | -14% | |
| 40Moderate | Kiniksa Pharmaceuticals International, plc | Mark Ragosa CHIEF FINANCIAL OFFICER | $1.7M 36,722 shares | -75% | |
| 4Weak | Kiniksa Pharmaceuticals International, plc | Barry D Quart director | $126k 2,800 shares | -22% | |
| 37Weak | Kiniksa Pharmaceuticals International, plc | Mark Ragosa CHIEF FINANCIAL OFFICER | $772k 17,845 shares | -60% | |
| 29Weak | Kiniksa Pharmaceuticals International, plc | Barry D Quart director | $722k 15,960 shares | -119% | |
| 30Weak | Kiniksa Pharmaceuticals International, plc | Mark Ragosa CHIEF FINANCIAL OFFICER | $503k 12,000 shares | -39% | |
| 38Weak | Kiniksa Pharmaceuticals International, plc | Barry D Quart director | $836k 20,129 shares | -62% | |
| 28Weak | Kiniksa Pharmaceuticals International, plc | Eben Tessari CHIEF OPERATING OFFICER | $501k 12,048 shares | -42% | |
| 47Moderate | Kiniksa Pharmaceuticals International, plc | Mark Ragosa CHIEF FINANCIAL OFFICER | $1.8M 42,841 shares | -58% | |
| 0Weak | Kiniksa Pharmaceuticals International, plc | Eben Tessari CHIEF OPERATING OFFICER | $8,578 200 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.